A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Ispinesib (Primary) ; Carboplatin
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 05 Jan 2007 Status change
- 15 Oct 2005 New trial record.